Pre-transplant minimal residual disease in children with acute lymphoblastic leukemia.
Mehta
Parinda A
PA
Division of Hematology/Oncology, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. Parinda.Mehta@cchmc.org
Davies
Stella M
SM
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D015322:Gene Rearrangement, B-Lymphocyte / Q000235:genetics; D015329:Gene Rearrangement, T-Lymphocyte / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000401:mortality; D007223:Infant; D017710:Lymphocyte Transfusion / Q000401:mortality; D008297:Male; D008991:Monitoring, Physiologic; D018365:Neoplasm, Residual / Q000235:genetics / Q000401:mortality*; D016133:Polymerase Chain Reaction; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000401:mortality* / Q000628:therapy; D011237:Predictive Value of Tests; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors; D014184:Transplantation, Homologous; D016896:Treatment Outcome